Antibiotics for pre-term pre-labour rupture of membranes: prevention of neonatal deaths due to complications of pre-term birth and infection. by Cousens, Simon et al.
Cousens, S; Blencowe, H; Gravett, M; Lawn, JE (2010) Antibiotics for
pre-term pre-labour rupture of membranes: prevention of neonatal
deaths due to complications of pre-term birth and infection. Interna-
tional journal of epidemiology, 39 Suppl 1. i134-43. ISSN 0300-5771
Downloaded from: http://researchonline.lshtm.ac.uk/3908/
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Creative Commons Attribution Non-commercial No Derivatives
http://creativecommons.org/licenses/by-nc-nd/2.5/
Antibiotics for pre-term pre-labour rupture
of membranes: prevention of neonatal
deaths due to complications of pre-term
birth and infection
Simon Cousens,1 Hannah Blencowe,1 Michael Gravett2 and Joy E Lawn3,4
1Infectious Disease Epidemiology Unit, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK.
2Department of OB/GYN, University of Washington, Seattle, Washington, USA. 3Saving Newborn Lives/Save the Children-USA,
11 South Way, Pinelands, Cape Town 7405, South Africa. 4Health Systems Strengthening Unit, Medical Research Council,
South Africa.
Corresponding author. London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK.
E-mail: simon.cousens@lshtm.ac.uk
Background In high-income countries, it is standard practice to give antibiotics
to women with pre-term, pre-labour rupture of membranes
(pPROM) to delay birth and reduce the risk of infection. In low
and middle-income settings, where some 2 million neonatal deaths
occur annually due to complications of pre-term birth or infection,
many women do not receive antibiotic therapy for pPROM.
Objectives To review the evidence for and estimate the effect on neonatal
mortality due to pre-term birth complications or infection, of
administration of antibiotics to women with pPROM, in low and
middle-income countries.
Methods We performed a systematic review to update a Cochrane review.
Standardized abstraction forms were used. The quality of the evi-
dence provided by individual studies and overall was assessed using
an adapted GRADE approach.
Results Eighteen RCTs met our inclusion criteria. Most were from
high-income countries and provide strong evidence that antibiotics
for pPROM reduce the risk of respiratory distress syndrome [risk ratio
(RR)¼ 0.88; confidence interval (CI) 0.80, 0.97], and early onset
postnatal infection (RR¼ 0.61; CI 0.48, 0.77). The data are consistent
with a reduction in neonatal mortality (RR¼ 0.90; CI 0.72, 1.12).
Conclusion Antibiotics for pPROM reduce complications due to pre-term deliv-
ery and post-natal infection in high-income settings. There is mod-
erate quality evidence that, in low-income settings, where access to
other interventions (antenatal steroids, surfactant therapy, ventila-
tion, antibiotic therapy) may be low, antibiotics for pPROM could
prevent 4% of neonatal deaths due to complications of prematurity
and 8% of those due to infection.
Keywords Neonatal mortality, newborn care, antibiotics, pre-term birth,
prematurity, infection, respiratory distress syndrome
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Background
Each year almost 4 million newborns die.1 Complica-
tions of pre-term birth and infections account for
more than half of these deaths. Pre-term, pre-labour
rupture of membranes (pPROM) occur when the
amniotic sac enclosing the fetus ruptures before 37
weeks of gestation (pre-term) and prior to the onset
of labour (pre-labour). It is associated with about
one-third of pre-term deliveries in high-income coun-
tries, and is associated with increased rates of neona-
tal and maternal infection.2 Infection may be a cause
of or result from pPROM.3 Empiric antibiotic therapy
following pPROM has been demonstrated in
high-income countries to increase the time period
between pPROM and delivery, and reduce the risks
of maternal and neonatal infection.2 Neonatal infec-
tions and prematurity are important causes of neona-
tal death in low and middle-income countries
(LMICs). We therefore reasoned that empiric antibi-
otic therapy following pPROM may be an efficacious
and cost-effective intervention to prevent infection
and improve neonatal outcomes in LMICs as well.
A systematic review of randomized trials of antibi-
otics for pPROM has been published in the Cochrane
database.3 This included 22 trials including over 6000
women and concluded that antibiotic administration
following pPROM delays delivery and reduces major
markers of neonatal morbidity. The authors conclude
that the data support the routine use of antibiotics in
pPROM but counsel against the use of co-amoxiclav
as this was associated with increased risk of neonatal
necrotizing enterocolitis.3 In this article, we present
an update of this review.
Objective
To review the evidence for, and estimate the effect on
neonatal mortality due to the direct complications of
pre-term birth and due to infections, of antibiotics
administered to women with pPROM, compared with
no treatment, for low and middle-income countries.
Methods
Searches
We reviewed the 22 trials included in the Cochrane
review3 and abstracted data on the outcomes of inter-
est, namely neonatal mortality, and the incidence
of severe morbidity relating to pre-term delivery or
infection: necrotizing enterocolitis, intra-ventricular
haemorrhage, respiratory distress syndrome (RDS),
confirmed sepsis. We excluded two trials in which
all women received antibiotic treatment for 3 or 7
days.4,5 We also excluded three trials which compared
co-amoxiclav with placebo or no antibiotic treat-
ment6–8 and the co-amoxiclav arm of another
trial[9] because of the evidence that co-amoxiclav is
associated with increased risk of necrotizing
enterocolitis. We therefore included 17 trials from
the Cochrane review.9–25
We also undertook systematic searches in multi-
ple databases to identify studies of antibiotics for
pPROM. We searched PubMed, Cochrane Libraries
and all World Health Organization Regional
Databases, and included publications in any language.
Search terms included: ‘preterm/premature’, ‘mem-
branes’, ‘rupture,’ ‘antibiotics’. For PubMed, we further
restricted the search to randomized/clinical trials.
Studies were included if data were reported on mor-
tality or severe morbidity (see above) during the
neonatal period.
Inclusion/exclusion criteria, abstraction
We included randomized trials from any setting and
observational studies from low and middle-income
settings. Studies were included if antibiotics were
given alone or in combination with antenatal steroids
and surfactants. For all outcomes, the denominator
used was the number of liveborn babies. Data from
all studies which met the inclusion criteria were
abstracted using a standardized form. We abstracted
key variables with regard to the study identifiers and
context, study design and limitations, the interven-
tion, application of intention-to-treat analysis and
the outcomes of interest (neonatal mortality and the
incidence of severe morbidity relating to pre-term
delivery or infection). We assessed the quality of the
evidence provided by each of these studies using a
standard table (webtable) employing an adapted ver-
sion of GRADE26 developed by the Child Health
Epidemiology Reference Group (CHERG).27
Analysis and summary measures
Statistical analyses to summarize results across stu-
dies were performed using Stata version 10 software
(http://www.stata.com). We performed and presented
the results from fixed effects meta-analyses for those
outcomes for which the evidence of heterogeneity
between studies was weak (P40.1). Otherwise, we
performed and presented the results of random effects
meta-analyses. We summarized the overall quality of
evidence for each outcome using an adapted version
of the GRADE approach.27
Results
We identified 498 titles for screening and reviewed
the full text of 19 papers (Supplementary Table 1).
The search yielded one randomized trial which had
been published since the Cochrane review28 and one
observational study from a low-income setting.29
Randomized trials
We analysed data from 18 randomized trials and
4581 newborns (Table 1). Most trials were from
high-income settings. The exceptions were one
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trial from Turkey (31 newborns),12 one trial from
Mozambique (106 newborns)10 and one trial in Chile
(85 newborns).23 Most (14) trials were blinded through
the use of a placebo, but most were small with half
involving fewer than 100 women. The largest trial9 con-
tributed more than half of the total mothers (2415)
after exclusion of the arms receiving co-amoxiclav.
The studies are summarized in Table 1 and described
in more detail in the Supplementary table.
Description of the intervention
Women with pre-term rupture of membranes were
treated with antibiotics. The antibiotic used, dose
and duration varied between trials. Six trials used
ampicillin, four erythromycin, two penicillin and one
each used amoxicillin, mezlocillin, piperacillin. Two
studies used combinations of two or more of these
antibiotics, whereas one trial used a combination of
clindamycin and gentamycin.
Table 1 Summary of individual studies included in primary analyses
First
author
Year of
publication Country
Study
design Study participants
Antibiotics
used
Sample
size Reference
Almeida 1996 Mozambique RCT 30–36 weeks gestation Amoxicillin 110 [10]
Amon 1988 USA RCT 20–34 weeks gestation,
singleton pregnancies
Ampicillin 78 [11]
Camli 1997 Turkey RCT 28–34 weeks gestation,
singleton pregnancies
Ampicillin 31 [12]
Ernest 1994 USA RCT 21–37 weeks gestation Benzylpenicillin,
potassium
phenoxymethyl
penicillin
144 [13]
Fuhr 2006 Germany RCT 24.0–32.9 weeks gestation Mezlocillin 105 [28]
Garcia-
Burguillo
1996 Spain RCT <36 weeks gestation Erythromycin 58 [14]
Grable 1996 USA RCT 435 weeks gestation,
singleton pregnancies
Ampicillin 60 [15]
Johnston 1990 USA RCT 20–34 weeks gestation,
singleton pregnancies
Mezlocillin and
ampicillin
84 [16]
Kenyon 2001 UK and
others
RCT <37 weeks gestation,
multiple pregnancies
included
Erythromycin 2415 [9]
Kurki 1992 Finland RCT 23–36 weeks gestation, Penicillin 115 [17]
Lockwood 1993 USA RCT 20–34.9 weeks gestation,
singleton pregnancies
Piperacillin sodium 70 [18]
McGregor 1991 USA RCT 23–34 weeks gestation,
singleton pregnancies
Erythromycin 54 [19]
Mercer 1992 USA RCT 20–34.9 weeks gestation,
singleton
Erythromycin 216 [21]
Mercer 1997 USA RCT 24–32.0 weeks gestation,
included multiple
pregnancies
Ampicillin,
erythromycin,
amoxicillin
611 [20]
Morales 1989 USA RCT 26–34 weeks, singleton
pregnancies
Ampicillin 165 [22]
Ovalle Salas 1997 Chile RCT 24–34 weeks gestation Clindamycin and
gentamycin
85 [23]
Owen 1993 USA RCT 24–33.9 weeks gestation,
singleton
Ampicillin 117 [24]
Svare 1997 Denmark RCT 26þ 0–33.6 weeks gestation,
singleton pregnancies
Ampicillin,
pivampicillin,
metronidazole
67 [25]
Al-Qa’Qa 2005 Pakistan Observational 28–42 weeks gestation Unclear 225 [29]
i136 INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
Effect on all-cause neonatal mortality
Fifteen studies (4265 newborns) reported on neonatal
mortality (or mortality prior to discharge). A total of
284 deaths were reported (NMR¼ 66/1000 livebirths).
There was no evidence of heterogeneity between
studies (I2¼0%, P¼ 0.7). The summary, fixed effects,
risk ratio (RR) was 0.90 [95% confidence interval (CI)
0.72, 1.12; P¼ 0.33] (Figure 1, Table 2).
Effects on severe morbidity
Thirteen studies (4104 newborns) reported on the
occurrence of respiratory distress syndrome (1105
cases). There was no evidence of heterogeneity
between studies (I 2¼0%, P¼ 0.7). The summary,
fixed effects, risk ratio (RR) was 0.88 (95% CI 0.80,
0.97; P¼ 0.009) (Figure 2, Table 2).
Thirteen studies (4126 newborns) reported on the
risk of necrotizing enterocolitis (148 cases). There
was no evidence of heterogeneity between studies
(I2¼0%, P¼ 0.7). The summary, fixed effects,
risk ratio was 0.76 (95% CI 0.56, 1.05; P¼ 0.09)
(Figure 3, Table 2).
Twelve studies (1702 newborns) reported on the risk
of intra-ventricular haemorrhage (149 cases). One
study15 reported no cases and did not contribute to
the analysis. There was no evidence of heterogeneity
between studies (I2¼0%, P¼ 0.6). The summary,
fixed effects, risk ratio was 0.67 (95% CI 0.49, 0.92;
P¼ 0.01) (Figure 4, Table 2).
Thirteen studies (3693 newborns) reported on the
risk of confirmed sepsis (260 cases). There was no
evidence of heterogeneity between studies (I2¼ 0%,
P¼ 0.6). The summary, fixed effects, risk ratio was
0.61 (95% CI 0.48, 0.77; P< 0.001) (Figure 5, Table 2).
In 6 of the 18 trials (2860 babies),9,10,12,14,19,21 only
oral antibiotics were used. In meta-regression analy-
ses, there was no strong evidence that any of the
above effects differed between trials using IV antibi-
otics and those using oral antibiotics only (P40.15 for
all outcomes).
Studies in low and middle-income countries
Very few data are available from low and
middle-income countries. One trial in Mozambique10
included 106 newborns and reported 11 deaths and
12 cases of confirmed sepsis. Both the risk of death
(RR¼ 0.47) and risk of sepsis (RR¼ 0.17) appeared
lower in the treated arm. A trial in a middle-income
setting (Turkey,12) included 31 newborns and
reported a total of seven deaths and seven cases of
confirmed sepsis. Again, both the risk of death
(RR¼ 0.80) and the risk of sepsis (RR¼ 0.43)
appeared lower in the treated arm. Excluding one
death which occurred 10 min after delivery in a
baby with multiple malformations, the trial in
Overall  (I-squared = 0.0%, p = 0.719)
Kenyon (2001)
Almeida (1996)
Camli (1997)
Garcia (1995)
Kurki (1992)
McGregor (1991)
Amon (1988)
Morales (1989)
Mercer (1997)
Owen (1993)
Grable (1996)
Mercer (1992)
Study ID
Johnston (1990)
Lockwood (1993)
Ovalle Salas (1997)
0.90 (0.72, 1.12)
0.88 (0.65, 1.20)
0.47 (0.15, 1.52)
0.80 (0.21, 3.00)
0.62 (0.11, 3.45)
3.05 (0.13, 73.39)
11.00 (0.64, 189.65)
0.29 (0.03, 2.63)
0.52 (0.19, 1.45)
1.10 (0.59, 2.06)
0.56 (0.17, 1.82)
0.19 (0.01, 3.75)
1.43 (0.47, 4.35)
RR (95% CI)
1.10 (0.24, 5.14)
0.94 (0.14, 6.33)
1.43 (0.49, 4.16)
100.00
53.32
5.05
2.55
2.05
0.33
0.33
2.13
6.48
11.62
4.66
1.70
3.27
Weight
%
1.89
1.36
3.26
.1 .5 1 2 10
Figure 1 Fixed effects meta-analysis of the effect of antibiotics for pPROM on neonatal mortality
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Overall  (I-squared = 0.0%, p = 0.662)
Ovalle Salas (1997)
Study ID
Grable (1996)
Svare (1998)
Kenyon (2001)
Garcia (1996)
Johnston (1990)
Owen (1993)
Mercer (1997)
Lockwood (1993)
McGregor (1993)
Fuhr (2006)
Mercer (1992)
Morales (1990)
0.88 (0.80, 0.97)
0.32 (0.11, 0.89)
RR (95% CI)
0.62 (0.25, 1.53)
1.23 (0.27, 5.67)
0.91 (0.78, 1.07)
1.09 (0.42, 2.85)
0.60 (0.24, 1.47)
0.74 (0.50, 1.08)
0.83 (0.69, 0.99)
1.09 (0.75, 1.58)
0.96 (0.61, 1.52)
0.79 (0.33, 1.87)
1.15 (0.71, 1.85)
0.92 (0.62, 1.34)
100.00
2.19
%
Weight
1.58
0.46
44.61
1.06
1.78
5.49
25.32
3.50
2.60
1.68
4.05
5.68
.1 .5 1 2 10
Figure 2 Fixed effects meta-analysis of the effect of antibiotics for pPROM on the risk of respiratory distress syndrome
Table 2 Assessment of the quality of the evidence with respect to the effect of antibiotics for pPROM on severe neonatal
morbidity and mortality in low and middle-income settings
Assessment of quality of evidence Summary of Findings
No. of
studies Design Limitations Consistency
Directness No. of events
in total
RR (95% CI)
Generalizability
to low/middle-
income settings
Generalizability
to mortality
outcomes
Inter-
vention Control
Neonatal mortality: Quality of evidence: low
15 RCT No major Yes Low, mostly
high-income
Direct (all-cause) 133 151 RR¼ 0.90 (0.72, 1.12)
Severe morbidity (RDS): Quality of evidence: moderate
13 RCT No major Yes Low, mostly
high-income
Indirect (severe
morbidity)
509 596 RR¼ 0.88 (0.80, 0.97)
Severe morbidity (necrotizing enterocolitis): Quality of evidence: low
13 RCT No major Yes Low, mostly
high-income
Indirect (severe
morbidity)
63 85 RR¼ 0.76 (0.56, 1.05)
Severe morbidity (intra-ventricular haemorrhage): Quality of evidence: moderate
11 RCT No major Yes Low, mostly
high-income
Indirect (severe
morbidity)
59 90 RR¼ 0.67 (0.49, 0.92)
Severe morbidity (confirmed sepsis): Quality of evidence: moderate
13 RCT No major Yes Low, mostly
high-income
Indirect (severe
morbidity)
97 163 RR¼ 0.61 (0.48, 0.78)
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Overall  (I-squared = 0.0%, p = 0.546)
Grable (1996)
Ovalle Salas (1997)
Fuhr (2006)
Morales (1991)
Mercer (1992)
Garcia (1996)
Amon (1988)
Owen (1993)
Study ID
Lockwood (1993)
Johnston (1990)
McGregor (1994)
Mercer (1997)
0.67 (0.49, 0.91)
. (., .)
0.43 (0.12, 1.55)
0.25 (0.01, 5.00)
0.38 (0.13, 1.14)
0.80 (0.38, 1.68)
1.87 (0.18, 19.47)
0.57 (0.17, 1.87)
0.33 (0.04, 3.06)
RR (95% CI)
0.67 (0.24, 1.92)
0.39 (0.16, 0.99)
5.19 (0.65, 41.50)
0.83 (0.46, 1.48)
100.00
0.00
7.83
2.51
12.08
15.51
1.16
7.22
3.38
Weight
%
8.05
14.91
1.10
26.26
.1 .5 1 2 10
Figure 4 Fixed effects meta-analysis of the effect of antibiotics for pPROM on the risk of intra-ventricular haemorrhage
Overall  (I-squared = 0.0%, p = 0.672)
Fuhr (2006)
Lockwood (1993)
Owen (1993)
McGregor (1994)
Grable (1996)
Mercer (1997)
Ovalle Salas (1997)
Amon (1988)
Svare (2000)
Johnston (1990)
Study ID
Kenyon (2001)
Mercer (1992)
Morales (1993)
0.76 (0.56, 1.05)
0.41 (0.04, 3.83)
4.73 (0.24, 95.09)
3.93 (0.87, 17.74)
0.52 (0.10, 2.60)
0.94 (0.06, 14.27)
0.41 (0.17, 0.96)
0.34 (0.01, 8.14)
1.07 (0.31, 3.69)
0.41 (0.02, 9.68)
0.73 (0.13, 4.17)
RR (95% CI)
0.78 (0.47, 1.30)
0.68 (0.29, 1.60)
0.69 (0.12, 4.03)
100.00
3.15
0.60
2.37
4.61
%
1.21
20.69
1.74
5.06
1.58
3.36
Weight
38.20
13.96
3.46
.1 .5 1 2 10
Figure 3 Fixed effects meta-analysis of the effect of antibiotics for pPROM on the risk of necrotizing enterocolitis
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Chile23 reported 12 neonatal deaths, 7 of which
occurred in the group receiving antibiotics
(RR¼ 1.43). RDS (17 cases, RR¼ 0.32), necrotizing
enterocolitis (1 case, control arm), intra-ventricular
haemorrhage (10 cases, RR¼ 0.43) and early onset
sepsis (4 cases, RR¼ 0.34) were all, if anything, less
common in the intervention arm.
These data are consistent with one trial and one
observational study from low and middle-income
countries that we excluded from our primary analysis.
We excluded from our main analyses a trial con-
ducted in Zimbabwe8 because it used co-amoxiclav,
This trial included 168 newborns and reported 19
deaths and 34 cases of unconfirmed clinical sepsis.
Both the risk of death (RR¼ 0.76) and the risk of
unconfirmed sepsis (RR¼ 0.65) appeared lower in
the treated arm. In an observational study conducted
in Pakistan,29 225 newborns were studied, of whom
140 were pre-term. It is not clear what antibiotics
mothers received though all newborns received anti-
biotics until a negative blood culture was obtained.
The risks of a positive blood culture (9% vs 30%),
RDS (25% vs 44%), necrotizing enterocolitis (3% vs
11%) and intra-ventricular haemorrhage (7% vs 12%)
were all lower in babies born to mothers who had
received antibiotics. Twenty neonatal deaths are
reported but it is not clear how these were distributed
between mothers who did or did not receive
antibiotics.
Discussion
There is high-quality evidence that antibiotics for
pPROM reduce the risk of complications due to pre-
maturity and risk of neonatal infection in
high-income settings. The evidence for a reduction
in neonatal mortality is less strong. Our meta-analysis
of 14 trials estimates a 10% reduction in all-cause
neonatal mortality but with a wide CI that included
no effect. However, there is a dearth of data from
low-income countries, where newborns have less
access to other forms of care including antenatal ster-
oids, surfactant therapy, ventilation and even antibi-
otic treatment for infection. In the absence of these
other interventions, the use of antibiotics for pPROM
will certainly prevent neonatal deaths by preventing
RDS, which is the most common cause of death due
to complications of prematurity. Similarly, in settings
in which newborns do not have easy access to anti-
biotic therapy for neonatal infections, the prevention
of sepsis cases through the use of antibiotics for
pPROM will certainly prevent infection deaths. We
did not observe strong evidence that oral antibiotics
were less effective than IVl antibiotics though our
power to detect any such difference is limited by
the small number of studies using oral antibiotics
only. Clearly, in low-income settings, oral-only regi-
mens will be easier to deliver than regimens involving
intravenous administration of the antibiotics.
Overall  (I-squared = 0.0%, p = 0.632)
Svare (1999)
Morales (1992)
Mercer (1992)
Kenyon (2001)
Ovalle Salas (1997)
Owen (1993)
Johnston (1990)
Almeida (1996)
Lockwood (1993)
Camli (1998)
Ernest (1994)
Kurki (1992)
Amon (1988)
Study ID
0.61 (0.48, 0.77)
0.62 (0.06, 6.48)
0.52 (0.16, 1.66)
0.95 (0.48, 1.87)
0.70 (0.52, 0.94)
0.34 (0.04, 3.15)
0.33 (0.07, 1.56)
0.22 (0.01, 4.44)
0.17 (0.04, 0.72)
0.63 (0.11, 3.54)
0.43 (0.10, 1.88)
0.17 (0.01, 3.57)
0.34 (0.01, 8.15)
0.14 (0.02, 1.13)
RR (95% CI)
100.00
1.09
4.79
%
9.06
60.11
1.81
3.69
1.45
6.68
1.88
2.95
1.63
0.91
3.94
Weight
.1 .5 1 2 10
Figure 5 Fixed effects meta-analysis of the effect of antibiotics for pPROM on the risk of confirmed sepsis
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There is evidence (P¼ 0.01) of a reduction in the
incidence of RDS (estimated reduction 12%, 95% CI
3–20%) with larger reductions in intra-ventricular
haemorrhage (33%, 95% CI 8–51%, P¼ 0.01) and
necrotizing enterocolitis (24%, 95% CI 5–44%,
P¼ 0.09) although the evidence for an effect on
necrotizing enterocolitis is relatively weak. Given
that RDS is the most common complication and has
the smallest effect estimate, we propose assuming
that antibiotics for pPROM can reduce deaths due
to complications of prematurity by 12% (uncertainty
range 3–20%) among newborns born following
pPROM. About one-third of pre-term deliveries are
associated with pPROM,2 so we propose an affected
fraction of 33% of all pre-term deaths. Thus, we esti-
mate that increasing coverage with antibiotics for
pPROM from 0% to 100% might prevent 4% of all
pre-term deaths.
Our analysis suggests a 39% reduction in incidence
of neonatal sepsis (95% CI 23–52%, P< 0.001) with
antibiotic therapy for pPROM among newborns born
following pPROM. In order to estimate by how much
this intervention might reduce sepsis deaths as a
whole, we need to take into account how many
sepsis deaths occur in pre-term babies and the propor-
tion of pre-term births with pPROM (assumed to be
one-third, see above). If 60% of neonatal sepsis deaths
occur in pre-term babies,30 one-third of which occur
after pPROM, then this implies that 20% of sepsis
deaths occur in pPROM babies. Thus, antibiotics
for pPROM might reduce sepsis deaths by about
8% overall (i.e. 39% reduction among 20% of deaths).
Potential benefits of empiric antibiotic therapy fol-
lowing pPROM must be weighed against possible
adverse consequences related to antibiotic administra-
tion. Most data have been reassuring, with no
increased adverse sequelae following empiric antibi-
otic therapy for pPROM.2,9,31 The ORACLE I trial,
the single largest reported, of nearly 5000 women
with pPROM randomized to either placebo or one of
several antibiotic regimens found neither increases
in immediate neonatal adverse sequelae related
to antibiotics nor differences in neurodevelopmental
outcome at 7 years of age.9,31 However, in a related
concurrent trial, empiric antibiotic therapy for
pre-term labour, without rupture of membranes, was
associated with an increased risk of neonatal necrotiz-
ing enterocolitis (associated with co-amoxiclav)
and of subsequent neurodevelopmental functional
impairment (associated with erythromycin) without
any significant prolongation in pregnancy or improve-
ment in other neonatal comorbidities.32,33 The reasons
for increases in neonatal morbidity following antibi-
otic therapy in pre-term labour remain speculative but
Box 1 Cause-specific mortality effect and quality grade of the estimate for antibiotics given to women with pPROM.
Causes of mortality to act on:
Direct complications of prematurity and infections.
Cause-specific effect and range:
Twelve percent reduction in incidence of RDS (95% CI 3–20%).
Thirty-nine percent reduction in incidence of neonatal sepsis (95% CI 22–52%)
We assume that these reductions in incidence of severe morbidity translate into similar reductions in mor-
tality amongst babies born to mothers with pPROM.
We assume that one-third of pre-term births are related to pPROM and that 60% of infection deaths are
related to prematurity.
Thus, we estimate that giving antibiotics to mothers with pPROM could reduce neonatal deaths due to the
direct complications of pre-term birth by 4% and neonatal deaths due to sepsis by 8%.
Quality of input evidence:
Moderate
18 RCTs, but mainly from high-income settings. Evidence strong for an effect on severe morbidity but less
strong for an effect on mortality. The few data available from low/middle-income countries are consistent
with an effect on mortality.
Proximity of the data to cause specific mortality effect:
Moderate (severe morbidity)
Limitations:
The control groups in most or all of these studies will have had access to a high level of routine care whereas
the group of interest for programmes in low-income countries are newborns currently receiving little or no
medical care.
Possible adverse effects:
Co-amoxiclav is not recommended as it has been associated with an increased risk of necrotizing
enterocolitis.
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may relate to disruptions in the microbial colonization
of the neonatal gut by low- virulence microflora that
has recently been demonstrated to begin in utero, even
with intact fetal membranes, allowing subsequent col-
onization by more virulent micro-organisms following
birth.34 In contrast, antibiotic therapy following
pPROM may prevent the ascending colonization of
amniotic fluid by more virulent strains arising from
the maternal lower genital tract, thereby reducing
neonatal infections.
Empiric antibiotic therapy following pPROM reduces
risk of neonatal respiratory distress, intra-ventricular
haemorrhage and confirmed neonatal sepsis. Whereas
most of the data supporting this conclusion derive from
studies performed in high-income countries, the limited
data from low and middle-income countries suggest
similar reductions in neonatal morbidity. Empiric anti-
biotic therapy following pPROM represents an effica-
cious and low cost intervention to improve neonatal
outcomes. Studies to assess translational feasibility of
this intervention and to track its coverage in low and
middle-income countries are urgently needed.
Conclusion
Although there are many trials and the results of
these trials are quite consistent, we have graded the
overall evidence quality as moderate because of the
limited evidence from low and middle-income set-
tings, and the fact that the strong evidence of effec-
tiveness is for severe morbidity rather than mortality.
In order to estimate mortality effects, we have had to
make certain assumptions and in doing so we have
tried to be conservative. In low-income settings where
infections in pregnancy are more prevalent, yet
the available care for mothers and for babies is
much more limited, the impact of antibiotic therapy
may be greater than in high-income settings.
Nevertheless, we propose that, amongst births compli-
cated by pPROM, empiric antibiotic therapy could
reduce deaths due to complications of prematurity
by 12% and deaths due to sepsis by 39%. Taking
account of the proportion of births affected by
pPROM and the proportion of sepsis deaths that
may occur in pre-term babies in low-income settings,
these effects translate into a 4% reduction in all
deaths due to complications of prematurity and an
8% reduction in all deaths due to neonatal sepsis.
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